These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31187470)

  • 1. Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL
    Clin Pharmacokinet; 2019 Jul; 58(7):973-975. PubMed ID: 31187470
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' Reply to Coste et al.: "Levothyrox
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL
    Clin Pharmacokinet; 2019 Jul; 58(7):967-968. PubMed ID: 31161455
    [No Abstract]   [Full Text] [Related]  

  • 3. Authors' Reply to Yu et al.: "Levothyrox
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL
    Clin Pharmacokinet; 2020 Feb; 59(2):283-285. PubMed ID: 31802402
    [No Abstract]   [Full Text] [Related]  

  • 4. Authors' Reply to Lechat et al.: "Levothyrox
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL
    Clin Pharmacokinet; 2019 Oct; 58(10):1353-1354. PubMed ID: 31452151
    [No Abstract]   [Full Text] [Related]  

  • 5. Author's Reply to Trechot: "Comment on Levothyrox
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL
    Clin Pharmacokinet; 2019 Jul; 58(7):979-980. PubMed ID: 31187472
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on: Levothyrox
    Tréchot P
    Clin Pharmacokinet; 2019 Jul; 58(7):977-978. PubMed ID: 31187471
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on "Levothyrox
    Munafo A; Krebs-Brown A; Gaikwad S; Urgatz B; Castello-Bridoux C
    Clin Pharmacokinet; 2019 Jul; 58(7):969-971. PubMed ID: 31187469
    [No Abstract]   [Full Text] [Related]  

  • 8. Comment on: "Levothyrox
    Coste J; Bertagna X; Zureik M
    Clin Pharmacokinet; 2019 Jul; 58(7):965-966. PubMed ID: 31161457
    [No Abstract]   [Full Text] [Related]  

  • 9. Comment on: "Levothyrox
    Nicolas P
    Clin Pharmacokinet; 2019 Jul; 58(7):959-960. PubMed ID: 31161454
    [No Abstract]   [Full Text] [Related]  

  • 10. Comment on "Levothyrox
    Hoermann R; Midgley JEM; Larisch R; Dietrich JW
    Clin Pharmacokinet; 2020 May; 59(5):655-657. PubMed ID: 32236910
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on "Levothyrox
    Yu Y; Maliepaard M
    Clin Pharmacokinet; 2020 Feb; 59(2):281-282. PubMed ID: 31802403
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on: "Levothyrox
    Lechat P; Ropers J; Barré J; Mouly S
    Clin Pharmacokinet; 2019 Oct; 58(10):1351-1352. PubMed ID: 31452152
    [No Abstract]   [Full Text] [Related]  

  • 13. Authors' Reply to Nicolas: "Levothyrox
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL
    Clin Pharmacokinet; 2019 Jul; 58(7):961-963. PubMed ID: 31161456
    [No Abstract]   [Full Text] [Related]  

  • 14. Levothyrox
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran A; Toutain PL
    Clin Pharmacokinet; 2019 Jul; 58(7):827-833. PubMed ID: 30949873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Authors' Reply to Krebs-Brown et al. Comment on: "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?".
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL
    Clin Pharmacokinet; 2020 Feb; 59(2):269-271. PubMed ID: 31802401
    [No Abstract]   [Full Text] [Related]  

  • 16. The French Levothyrox
    Mouly S; Roustit M; Bagheri H; Perault-Pochat MC; Molimard M; Bordet R
    Therapie; 2019 Jun; 74(3):431-435. PubMed ID: 30737052
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to the letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by S. Montenegro, C. Helwig, J.-E. Schwarze, C. Castello-Bridoux, S. Marque, M. Lispi, et al. (J Gynecol Obstet Hum Reprod. 2023;52(8):102640).
    Barriere P; Arbo E; Jenkins J
    J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102644. PubMed ID: 37573940
    [No Abstract]   [Full Text] [Related]  

  • 18. [Lévothyrox
    Wémeau JL; Ladsous M
    Presse Med; 2017 Oct; 46(10):887-889. PubMed ID: 29108724
    [No Abstract]   [Full Text] [Related]  

  • 19. Spontaneous adverse event notifications by patients subsequent to the marketing of a new formulation of Levothyrox
    Viard D; Parassol-Girard N; Romani S; Van Obberghen E; Rocher F; Berriri S; Drici MD
    Fundam Clin Pharmacol; 2019 Aug; 33(4):463-470. PubMed ID: 30575110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?
    Concordet D; Gandia P; Montastruc JL; Bousquet-Mélou A; Lees P; Ferran AA; Toutain PL
    Clin Pharmacokinet; 2020 Jan; 59(1):1-5. PubMed ID: 31432471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.